UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the |
| Date of Report: October 17, 2014 (Date of earliest event reported) | ||||
| Theravance, Inc. (Exact name of registrant as specified in its charter) | ||||
| Delaware (State or other jurisdiction of incorporation) | 000-30319 (Commission File Number) | 94-3265960 (IRS Employer Identification Number) | ||
| 951 Gateway Boulevard, South San Francisco, CA (Address of principal executive offices) | 94080 (Zip Code) | |||
650-238-9600 (Registrant's telephone number, including area code) | ||||
| Not Applicable (Former Name or Former Address, if changed since last report) | ||||
| Item 8.01. Other Events On October 17, 2014, GlaxoSmithKline plc (GSK) and Theravance, Inc. issued a press release announcing that Respiratory Medicine has published positive results from a third lung function study comparing the efficacy and safety of ANORO(R) ELLIPTA(R) (umeclidinium/vilanterol, 'UMEC/VI'), the combination long-acting muscarinic antagonist (LAMA)/long-acting beta2-adrenergic agonist (LABA), with the LAMA tiotropium, administered in the HandiHaler(R) inhaler, to patients with chronic obstructive pulmonary disease. UMEC/VI has been developed under the LABA collaboration agreement between Glaxo Group Limited and Theravance, Inc. A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference. Item 9.01. Financial Statements and Exhibits (d) Exhibits Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. |
| Dated: October 17, 2014 | THERAVANCE, INC. By: /s/ Michael W. Aguiar |
| Exhibit No. | Description |
| 99.1 | Press Release dated October 17, 2014 |
